Tag: COVID-19 antibodies

1. An interval of 44-45 weeks between the first and second dose resulted in a four-fold increase in median antibody titers, 28-days after administration, compared to the standard interval of 8-12 weeks. 2. A two-fold increase in median IgG levels was observed among patients 28-days after receiving their third dose...
Levels of antibodies against the trimeric spike protein and receptor-binding domain were 36- and 77-fold higher in the BNT162b2 group compared to control. There were no vaccine-related serious adverse events. Evidence Rating Level: 1 (Excellent)  Study Rundown: Current research on COVID-19 vaccination has revolved around a homologous dosing schedule (administering the...
1. Levels of antibodies against the trimeric spike protein and receptor-binding domain were 36- and 77-fold higher in the BNT162b2 group compared to control. 2. There were no vaccine-related serious adverse events. Evidence Rating Level: 1 (Excellent)  Study Rundown: Current research on COVID-19 vaccination has revolved around a homologous dosing schedule (administering...
1. A similar proportion of patients died within 28 days of randomization in both groups (high-titre convalescent plasma vs. usual care). 2. Allocation to convalescent plasma had no significant effect on the proportion of patients discharged from hospital within 28 days. Evidence Rating Level: 1 (Excellent) Study Rundown: Convalescent plasma is a...
1. In this cross-sectional study of Japanese patients with cancer and health care workers, the seroprevalence of SARS-CoV-2 antibodies did not differ between the two cohorts. 2. However, results suggest that comorbid cancer and treatment with systemic therapy, including chemotherapy and immune checkpoint inhibitors, may be associated with differences in...
1. There was a vaccine efficacy of 97.2% against symptomatic COVID-19 infection in individuals at least 7 days after their second vaccine dose. 2. Substantial and consistent declines in COVID-19 incidence corresponded to greater vaccine coverage. Evidence Rating Level: 2 (Good) Study Rundown: Beyond clinical trials, there is growing evidence of the...
1. Vaccinated individuals reported fewer SARS-CoV-2 infections and a lesser proportion of cases were symptomatic compared to the unvaccinated cohort. 2. BNT162b2 mRNA vaccine showed an effectiveness of 70% 21 days after a single dose. Evidence Rating Level: 2 (Good)  Study Rundown: The BNT162b2 mRNA (Pfizer-BioNTech) and ChAdOx1 nCoV-19 adenoviral (Oxford-AstraZeneca) COVID-19...
1. The initial doses of the Pfizer and AstraZeneca vaccines were 91% and 88% efficacious in reducing COVID-19 hospitalizations one month after vaccination. 2. Combined vaccine efficacy of the Pfizer and AstraZeneca in preventing hospital admission due to COVID-19 among those aged 80 years and older was approximately 83%. Evidence Rating...
1. Previous infection from SARS-CoV-2 was linked to an 84% lower incidence of reinfection. 2. Median interval between primary infection and reinfection of COVID-19 was greater than 200 days. Evidence Rating Level: 2 (Good) Study Rundown: While it has been suggested that a history of SARS-CoV-2 infection confers protection against subsequent infection,...
1. 80% of patients in the azithromycin plus usual care group reported feeling recovered within 28 days, compared to 77% in the usual care group. 2. Safety outcomes were similar in both groups with 1% of patients reporting hospital admission and no deaths. Evidence Rating Level: 1 (Excellent) Study Rundown: Treatments that...